Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

39.23
+1.413.73%
Post-market: 39.10-0.1300-0.33%16:33 EDT
Volume:1.82M
Turnover:71.42M
Market Cap:3.36B
PE:-9.04
High:39.85
Open:38.49
Low:38.34
Close:37.82
Loading ...

Crispr Therapeutics Is Maintained at Equal-Weight by Barclays

Dow Jones
·
12 Feb

Crispr Therapeutics price target raised to $56 from $55 at Barclays

TIPRANKS
·
12 Feb

Crispr Therapeutics AG (CRSP) Receives a Hold from Barclays

TIPRANKS
·
12 Feb

CRISPR Therapeutics Ag : RBC Cuts Target Price to $48 From $53

THOMSON REUTERS
·
12 Feb

Crispr Therapeutics AG’s Financial Challenges: Sell Rating Due to Casgevy Program Burden

TIPRANKS
·
12 Feb

CRISPR Therapeutics Ag : Truist Securities Raises Target Price to $120 From $100

THOMSON REUTERS
·
12 Feb

Crispr Therapeutics AG: Strategic Collaborations and Promising Pipeline Drive ‘Buy’ Rating

TIPRANKS
·
12 Feb

CRISPR Therapeutics Swings to Q4 Loss, Revenue Falls

MT Newswires Live
·
12 Feb

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Feb

CRISPR Therapeutics Q4 2024 GAAP EPS $(0.44) Beats $(1.13) Estimate, Sales $35.691M Beat $7.657M Estimate

Benzinga
·
12 Feb

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

BofA Securities Adjusts CRISPR Therapeutics Price Target to $86 From $85, Maintains Buy Rating

MT Newswires Live
·
11 Feb

Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities

TIPRANKS
·
11 Feb

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Zacks
·
11 Feb

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand

Reuters
·
11 Feb

Truist Financial Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
10 Feb

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Motley Fool
·
10 Feb

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Zacks
·
07 Feb

CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey
·
07 Feb

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Zacks
·
06 Feb